http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2272025-C2
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 |
| filingDate | 2000-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_876bd1bd6fbcf13c69f0b44c76d9dcff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b919a54bcdab3eec533ce1bb95701ae5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b84472be2f7f98f22de0b525c8f6ba5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_654076f9d8b3cd16e73cf2e323148274 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2859990bbdebb73701a7a568f4f12b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e59ef40b24da1d32264a2e269f38f30a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7aee7efd4719d1223faa083820e1ad9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d39637d53d9ec4182a1318f73ab2be3e |
| publicationDate | 2006-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2272025-C2 |
| titleOfInvention | Derivatives of adamantane, methods for their preparing, pharmaceutical composition based on thereof and method for its preparing, methods for treatment of rheumatic arthritis and lung chronic obstructive disease |
| abstract | FIELD: organic chemistry, medicine, pharmacy. n SUBSTANCE: invention relates to derivatives of adamantine of the formula (I): wherein D represents -CH 2 or -CH 2 -CH 2 ; E represents -C(O)NH or -NHC(O); each R 1 and R 2 represents independently hydrogen atom or halogen atom but R 1 and R 2 can't mean hydrogen atom simultaneously; R 3 represents group of the formula: -R 4 -X-R 5 (II) wherein R 4 represents (C 1 -C 6 )-alkyl group; X represents oxygen or sulfur atom or the group NR 13 ; R 5 represents (C 1 -C 6 )-alkyl or (C 2 -C 6 )-alkenyl and each of them can be optionally substituted with at least one substitute taken among halogen atom, hydroxyl, di-(C 1 -C 6 )-alkylamino-group, -Y-R 6 , , and 5- or 6-membered heteroaromatic ring comprising 1-4 heteroatoms taken independently among nitrogen atom wherein heteroaromatic ring can be optionally substituted with at least one (C 1 -C 6 )-alkyl; Y represents oxygen or sulfur atom or the group -NH; R 6 represents the group -R 7 Z wherein R 7 represents (C 2 -C 6 )-alkyl group and Z represents -OH; when Y represents oxygen or sulfur atom or the group -NH then R 6 represents additionally hydrogen atom, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylcarbonyl; R 13 represents hydrogen atom, (C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkylmethyl; or R 13 represents (C 1 -C 6 )-alkyl group optionally substituted with at least one hydroxyl, or to its pharmaceutically acceptable salts or solvates. These compounds are effective antagonists of P2X 7 receptors and can be used in treatment of rheumatic arthritis or lung chronic obstructive disease. Also, invention describes methods for preparing these compounds, pharmaceutical composition comprising indicated compounds, method for preparing pharmaceutical composition and their using in therapy. n EFFECT: improved preparing and treatment methods, valuable medicinal properties of compounds and composition. n 19 cl, 1 tbl, 77 ex |
| priorityDate | 1999-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 364.